CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy

SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Clinical Safety and Efficacy Measures With Both CYPHER(R) Stent and XIENCE V(R) Stent

WATERLOO, Belgium, September 30, 2010 - Investigators reported results of SORT-OUT IV, comparing Cordis
Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE
V (R) Everolimus-eluting Stent in the primary endpoint of MACE (major acute
coronary events) at nine months. These findings were presented the week
commencing 20th September 2010 at the TCT Congress, one of the largest
cardiovascular industry events held annually in Washington DC. This study
adds to the unmatched body of clinical safety and efficacy data on the
CYPHER(R) Stent with this comparison to the more recently approved XIENCE
V(R) Stent in a contemporary setting.

"The SORT OUT consortium has used CYPHER(R) Stent as the comparator in a
number of studies and to date, no newer stent has proven a benefit over
CYPHER(R) Stent in terms of clinical safety or efficacy," said Campbell
Rogers, M.D., Chief Scientific Officer and Head, Global Research and
Development, Cordis Corporation. "The clinical safety and efficacy of the
CYPHER(R) Stent in this real-world randomized study reinforce the excellent
sustained clinical outcomes consistently seen over the last 10 years."

The large randomized trial SORT OUT IV included more than 2,600 patients
across a wide range of lesion and patient complexity. The study was designed
to test whether the XIENCE V(R) stent is non-inferior to the CYPHER(R) Stent.
Both drug-eluting stents performed better than planned for the composite
endpoint of MACE (4.9 % for XIENCE V(R) Stent vs. 5.2% for CYPHER(R) Stent);
these data support the non-inferiority of the XIENCE V(R) stent over the
CYPHER(R) stent (non-inferiority p=0.01) . There was no statistically
significant difference in key markers of safety including the incidence of
cardiac death (1.9% for XIENCE V(R) Stent vs. 1.4% for CYPHER(R) Stent:
p=0.31), myocardial infarction, (1.1% for XIENCE V(R) Stent vs. 1.4% for
CYPHER(R) Stent: p=0.48), or definite or probable stent thrombosis (0.9% for
XIENCE V(R) Stent vs. 0.9% for CYPHER(R) Stent: p=0.83).

"CYPHER remains an essential treatment option for today's interventional
cardiologist considering its unsurpassed clinical safety and efficacy proven
out to 10 years and the 7 extended indications (e.g. diabetes, AMI, multi
vessel disease) in which CYPHER(R) stent specifically demonstrated superior
outcomes," said Rogers.

Notes to Editors:

CYPHER(R) Sirolimus-eluting Coronary Stent in detail

The CYPHER(R) stent releases a unique anti-inflammatory and
anti-proliferative-type medicine, sirolimus, into the artery wall over a
period of 90 days. The sirolimus drug helps limit the overgrowth of normal
cells while the artery heals. The CYPHER(R) Stent has a unique closed-cell
design that allows the medicine to be distributed more evenly across the
treated area and that helps to keep the arteries open and the blood flowing
to the heart, reducing the chance of re-intervention in the treated area.
Eighty percent (80%) of the sirolimus drug is released during the first 30
days. The rest is released by the end of 90 days.

About CYPHER(R) stent studies

The CYPHER(R) Stent is the most studied drug-eluting stent in the world,
it has a proven safety profile out to 10 years and has been used in nearly 4
million patients worldwide. Today, with more than 9.000 citations on PubMed,
CYPHER(R) Sirolimus-eluting Coronary Stent is recognized as having the most
in depth clinical data, which marked it out as the most effective
drug-eluting stent available today with a clinical safety profile presenting
minimal risks. CYPHER's(R) body of clinical evidence is completely unmatched
by any other drug-eluting stent. The CYPHER(R) Stent has consistently proven
to control late loss across all vessel sizes and across a broad patient
population, even in the most complex types of patients such as patients with
diabetes and acute myocardial infarction. In fact, the CYPHER(R) Stent has
shown more than 70% risk reduction in target lesion revascularization (TLR)
when compared with bare metal stents.

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson &
Johnson company, has been a worldwide leader in the development and
manufacture of interventional vascular technology. Through the company's
innovation, research and development, Cordis partners with interventional
cardiologists worldwide to treat millions of patients who suffer from
vascular disease.

*Cordis Corporation has entered into an exclusive worldwide
license with Wyeth for the localized delivery of sirolimus in certain fields
of use, including delivery via vascular stenting. Sirolimus, the active drug
released for the stent, is marketed by Wyeth Pharmaceuticals, a division of
Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth
Pharmaceuticals.

**The third party trademarks used herein are trademarks of
their respective owners.

Ulrike Domany, Director PA& Communication, Cordis & Biosense Webster EMEA, (o) +43-1-36-025-396, (m) +43-664-83-504-83